Glenmark launches Covid drug after DCGI nod


NEW DELHI: Glenmark Pharmaceuticals on Saturday said it has launched antiviral drug Favipiravir, under the brand name FabiFlu, for the treatment of patients with mild to moderate COVID-19.
The Mumbai-based drug firm had on Friday received manufacturing and marketing approval from the Drugs Controller General of India (DCGI).
More on Covid-19

FabiFlu is the first oral Favipiravir-approved medication for the treatment of COVID-19, the company said in a statement.
“This approval comes at a time when cases in India are spiralling like never before, putting a tremendous pressure on our healthcare system,” Glenmark Pharmaceuticals chairman and managing director Glenn Saldanha said.
The company hopes that the availability of an effective treatment such as FabiFlu will considerably help assuage this pressure, and offer patients in India a much needed and timely therapy option, he added.



Source link

Please follow and like us:

Leave a Reply

Your email address will not be published. Required fields are marked *

Wordpress Social Share Plugin powered by Ultimatelysocial
Twitter
Pinterest
LinkedIn
Share